Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306

被引：0

作者：

Raymond, E. ^{[1
]}

Xu, J. ^{[2
]}

Kato, K. ^{[3
]}

Hubner, R. ^{[4
]}

Shu, Y. ^{[5
]}

Park, S. R. ^{[6
]}

Kojima, T. ^{[7
]}

Wyrwicz, L. S. ^{[8
]}

Tougeron, D. ^{[9
]}

Geboes, K. ^{[10
]}

Van Cutsem, E. ^{[11
,12
]}

Pazo Cid, R. A. ^{[13
]}

Zaanan, A. ^{[14
]}

McLachlan, S-A. ^{[15
]}

Wu, H. ^{[16
]}

Shi, J. ^{[17
]}

Li, L. ^{[18
]}

Yan, S. ^{[19
]}

Yoon, H. ^{[20
]}

机构：

[1] Hop St Louis, AP HP, Clin Dev, Paris, France

[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Gastrointestinal Dept, Beijing 302 Hosp, Beijing, Peoples R China

[3] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan

[4] Christie NHS Fdn Trust, Clin Dev, Manchester, Lancs, England

[5] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China

[6] Univ Ulsan, Asan Med Ctr, Oncol Dept, Seoul, South Korea

[7] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[8] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland

[9] CHU Poitiers Jean Bernard Hop, Clin Dev, Poitiers, France

[10] UZ Gent Univ Hosp Ghent, Gastroenterol Dept, Ghent, Belgium

[11] Univ Hosp Gasthuisberg, Gastroenterol Digest Oncol, Leuven, Belgium

[12] Univ Leuven KU Leuven, Gastroenterol Digest Oncol, Leuven, Belgium

[13] Hosp Univ Miguel Servet, Med Oncol Dept, Zaragoza, Spain

[14] Hop Europeen Georges Pompidou, AP HP, Hepatogastroenterol & Digest Oncol, Paris, France

[15] GenesisCare St Vincents Hosp, Clin Dev, Melbourne, Vic, Australia

[16] BeiGene USA Inc, Stat & Data Sci, Ridgefield, NJ USA

[17] BeiGene Ltd, Clin Dev & Regulatory Off, Clin Biomarker, Beijing, Peoples R China

[18] BeiGene Ltd, Clin Dev & Regulatory Off, Clin Dev, Beijing, Peoples R China

[19] BeiGene Beijing Co Ltd, Clin Dev, Beijing, Peoples R China

[20] Mayo Clin, Dept Oncol, Rochester, MN USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.310

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

395MO

引用

页码：S159 / S159

页数：1

共 50 条

[41] Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
Hiroki Hara
Taroh Satoh
Takashi Kojima
Takahiro Tsushima
Yu Sunakawa
Morihito Okada
Ningning Ding
Hongqian Wu
Liyun Li
Tian Yu
Gisoo Barnes
Ken Kato
Esophagus, 2024, 21 : 102 - 110
[42] SHR-1701 plus chemotherapy as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
Wang, Yi
Liu, Hong
Wang, Qingwei
Qiao, Naian
Wang, Jianbo
Tan, Bingxu
Cheng, Bo
Chu, Yunxia
Li, Huajun
Cheng, Yufeng
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 363 - 363
[43] Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
Hara, Hiroki
Satoh, Taroh
Kojima, Takashi
Tsushima, Takahiro
Sunakawa, Yu
Okada, Morihito
Ding, Ningning
Wu, Hongqian
Li, Liyun
Yu, Tian
Barnes, Gisoo
Kato, Ken
ESOPHAGUS, 2024, 21 (02) : 102 - 110
[44] A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).
Xu, Jian-Ming
Kato, Ken
Hubner, Richard
Raymond, Eric
Xu, Yihuan
Liu, Sumei
Qazi, Ibrahim
Yoon, Harry H.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[45] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study
Kato, K.
Xu, R-H.
Oh, D-Y.
Bai, Y.
Shi, J.
Lee, K-W.
Hirano, H.
Xu, H.
Sheng, T.
Barnes, G.
ANNALS OF ONCOLOGY, 2024, 35 : S1456 - S1456
[46] A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N plus I) or nivolumab plus chemotherapy (N plus CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648.
Chau, Ian
Bridgewater, John A.
Wyrwicz, Lucjan
Greenwood, Mike
Blum, Steven I.
Moreno-Koehler, Alejandro
Worthy, Gill
Taylor, Fiona
Davis, Catherine
Chen, Clara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 251 - 251
[47] Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial
He, Mingming
Wang, Zhiqiang
Lu, Jin
Bai, Yuxian
Mao, Teng
Wang, Jun
Fan, Qingxia
Zhang, Yiping
Zhao, Kuaile
Chen, Zhendong
Gao, Shegan
Li, Jiancheng
Fu, Zhichao
Gu, Kangsheng
Liu, Zhihua
Wu, Lin
Zhang, Xiaodong
Feng, Jifeng
Niu, Zuoxing
Ba, Yi
Zhang, Helong
Liu, Ying
Zhang, Li
Min, Xuhong
Huang, Jing
Cheng, Ying
Wang, Dong
Sheng, Zhen
Zeng, Wanqin
Song, Li
Xu, Rui-Hua
Luo, Huiyan
MED, 2024, 5 (09):
[48] Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).
Van Cutsem, Eric
Kato, Ken
Ajani, Jaffer A.
Shen, Lin
Xia, Tianyu
Ding, Ningning
Zhan, Lin
Barnes, Gisoo
Kim, Sung-Bae
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16095 - E16095
[49] Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL)
Van Cutsem, Eric
Kato, Ken
Ajani, Jaffer A.
Shen, Lin
Xia, Tianyu
Ding, Ningning
Zhan, Lin
Barnes, Gisoo
Kim, Sung-Bae
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[50] Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China
He, Chaoneng
Mi, Xiufang
Xu, Gaoqi
Xu, Xinglu
Xin, Wenxiu
Zhong, Like
Zhu, Junfeng
Shu, Qi
Fang, Luo
Ding, Haiying
PLOS ONE, 2024, 19 (05):

← 1 2 3 4 5 →